Treatment of Nonmetastatic Castration-Resistant Prostate Cancer

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Patients with nonmetastatic castration-resistant prostate cancer (CRPC) are a heterogeneous population with regard to risk of progression to metastatic disease. Treatment selection for nonmetastatic CRPC must balance the risk of disease progression with the side effects of available therapies. Several medication classes are available for use in treating these patients, and other newer agents are under active clinical trial investigation. Here we review current therapies for nonmetastatic CRPC and discuss the recently completed and ongoing trials for this emerging disease state.

Original languageEnglish (US)
Pages (from-to)336-344
Number of pages9
JournalOncology (Williston Park, N.Y.)
Volume30
Issue number4
StatePublished - Apr 1 2016

Fingerprint

Castration
Prostatic Neoplasms
Disease Progression
Therapeutics
Clinical Trials
Population

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Treatment of Nonmetastatic Castration-Resistant Prostate Cancer. / Luo, Jia; Beer, Tomasz (Tom); Graff, Julie.

In: Oncology (Williston Park, N.Y.), Vol. 30, No. 4, 01.04.2016, p. 336-344.

Research output: Contribution to journalReview article

@article{8d62365d11044fe7895d407921609d81,
title = "Treatment of Nonmetastatic Castration-Resistant Prostate Cancer",
abstract = "Patients with nonmetastatic castration-resistant prostate cancer (CRPC) are a heterogeneous population with regard to risk of progression to metastatic disease. Treatment selection for nonmetastatic CRPC must balance the risk of disease progression with the side effects of available therapies. Several medication classes are available for use in treating these patients, and other newer agents are under active clinical trial investigation. Here we review current therapies for nonmetastatic CRPC and discuss the recently completed and ongoing trials for this emerging disease state.",
author = "Jia Luo and Beer, {Tomasz (Tom)} and Julie Graff",
year = "2016",
month = "4",
day = "1",
language = "English (US)",
volume = "30",
pages = "336--344",
journal = "ONCOLOGY (United States)",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "4",

}

TY - JOUR

T1 - Treatment of Nonmetastatic Castration-Resistant Prostate Cancer

AU - Luo, Jia

AU - Beer, Tomasz (Tom)

AU - Graff, Julie

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Patients with nonmetastatic castration-resistant prostate cancer (CRPC) are a heterogeneous population with regard to risk of progression to metastatic disease. Treatment selection for nonmetastatic CRPC must balance the risk of disease progression with the side effects of available therapies. Several medication classes are available for use in treating these patients, and other newer agents are under active clinical trial investigation. Here we review current therapies for nonmetastatic CRPC and discuss the recently completed and ongoing trials for this emerging disease state.

AB - Patients with nonmetastatic castration-resistant prostate cancer (CRPC) are a heterogeneous population with regard to risk of progression to metastatic disease. Treatment selection for nonmetastatic CRPC must balance the risk of disease progression with the side effects of available therapies. Several medication classes are available for use in treating these patients, and other newer agents are under active clinical trial investigation. Here we review current therapies for nonmetastatic CRPC and discuss the recently completed and ongoing trials for this emerging disease state.

UR - http://www.scopus.com/inward/record.url?scp=85047595131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047595131&partnerID=8YFLogxK

M3 - Review article

VL - 30

SP - 336

EP - 344

JO - ONCOLOGY (United States)

JF - ONCOLOGY (United States)

SN - 0890-9091

IS - 4

ER -